Puzzlingly, their findings have shown that ATO can also promote antioxidant activities by the upregulation of SESN2 in patient-derived primary S1 glioblastoma (GBM) cells, the U87MG glioma cell line, the human lung adenocarcinoma H1299 cell line and the A549 cell line. The gene discussed is SESN2; the disease is glioblastoma.